Aligos Therapeutics Inc (ALGS NASDAQ) stock market data APIs
$5.525
-0.08(-1.4%)
as of June 26, 2026
Try our APIs with
free plan!
Aligos Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Prev. Close
5.525
Open
5.4463
High
5.7325
Low
5.2786
52 wk Range
4.8-13.6892
Market Cap
34 499 K
Shares Outstanding
5 388 K
Revenue
4 705 K
EPS
-2.21
Beta
2.27
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aligos Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aligos Therapeutics Inc data using free add-ons & libraries
Get Aligos Therapeutics Inc Fundamental Data
Aligos Therapeutics Inc Fundamental data includes:
- Net Revenue: 4 705 K
- EBITDA: -94 589 000
- Earnings Per Share: -9
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-08
- EPS/Forecast: -2.3704
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aligos Therapeutics Inc News
New
Aligos Presents Promising Data For Pevifoscovir Sodium In Treating Hepatitis B
(RTTNews) - Aligos Therapeutics Inc. (ALGS), a clinical-stage biopharmaceutical company, on Wednesday presented positive data from ten presentations evaluating Pevifoscorvir sodium in treating chronic...
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoirData on the preclinical characteristics of the Aligos/Amoytop ASO progra...
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-...
Aligos Therapeutics GAAP EPS of -$2.21 beats by $0.04, revenue of $2.83M beats by $2.5M
* Aligos Therapeutics press release [https://seekingalpha.com/pr/20506698-aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2026-financial-results] (ALGS [https://seekingalpha.c...
Get Aligos Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
